West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West Pharmaceutical Services, Inc. WST is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.
West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Eric Green CEO | XFRA Exchange | 955306105 CUSIP |
| US Country | 10,600 Employees | 6 May 2026 Last Dividend | 27 Sep 2013 Last Split | 13 Jan 1978 IPO Date |
West Pharmaceutical Services, Inc. is a leading global provider in the design, manufacturing, and sale of containment and delivery systems for injectable drugs and healthcare products. With a presence across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, the company operates through two primary segments: Proprietary Products and Contract-Manufactured Products. Founded in 1923 and headquartered in Exton, Pennsylvania, West Pharmaceutical Services, Inc. is dedicated to serving biologic, generic, and pharmaceutical drug companies, as well as pharmaceutical, diagnostic, and medical device companies through a comprehensive sales force, distribution network, contract sales agents, and regional distributors.